Ignite Creation Date:
2025-12-25 @ 2:31 AM
Ignite Modification Date:
2025-12-28 @ 1:29 AM
Study NCT ID:
NCT04693234
Status:
COMPLETED
Last Update Posted:
2025-04-27
First Post:
2020-12-22
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
Sponsor:
BeiGene
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-02-15
Start Date Type:
ACTUAL
Primary Completion Date:
2022-06-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-08-31
Completion Date Type:
ACTUAL
First Submit Date:
2020-12-22
First Submit QC Date:
None
Study First Post Date:
2021-01-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-08-22
Results First Submit QC Date:
None
Results First Post Date:
2025-04-27
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-09
Last Update Post Date:
2025-04-27
Last Update Post Date Type:
ACTUAL